Alpharma To Market Institut Biochimique’s Flector NSAID Patch In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma plans to double its in-house sales force from 200 to 400 reps, plus add 200 contract sales reps to market Flector.
You may also be interested in...
Abraxis Buys Shimoda; Dyloject Stays With Javelin
Upfront cash seems “ridiculously low,” analyst tells “The Pink Sheet” DAILY.
Abraxis Buys Shimoda; Dyloject Stays With Javelin
Upfront cash seems “ridiculously low,” analyst tells “The Pink Sheet” DAILY.
Alpharma’s Flector NSAID Patch Off To A Strong Start, CEO Says
First topical NSAID patch garners 3,800 scripts in its first two weeks on the market.